100 related articles for article (PubMed ID: 11873385)
1. A method for identifying the financial burden of hospitalized infants on families.
Leader S; Jacobson P; Marcin J; Vardis R; Sorrentino M; Murray D
Value Health; 2002; 5(1):55-9. PubMed ID: 11873385
[TBL] [Abstract][Full Text] [Related]
2. Time and out-of-pocket costs associated with respiratory syncytial virus hospitalization of infants.
Leader S; Yang H; DeVincenzo J; Jacobson P; Marcin JP; Murray DL
Value Health; 2003; 6(2):100-6. PubMed ID: 12641860
[TBL] [Abstract][Full Text] [Related]
3. Costs of hospitalization with respiratory syncytial virus illness among children aged <5 years and the financial impact on households in Bangladesh, 2010.
Bhuiyan MU; Luby SP; Alamgir NI; Homaira N; Sturm-Ramirez K; Gurley ES; Abedin J; Zaman RU; Alamgir A; Rahman M; Ortega-Sanchez IR; Azziz-Baumgartner E
J Glob Health; 2017 Jun; 7(1):010412. PubMed ID: 28702175
[TBL] [Abstract][Full Text] [Related]
4. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
[TBL] [Abstract][Full Text] [Related]
6. Medical consumption and socioeconomic effects of infection with respiratory syncytial virus in The Netherlands.
Miedema CJ; Kors AW; Tjon A Ten WE; Kimpen JL
Pediatr Infect Dis J; 2001 Feb; 20(2):160-3. PubMed ID: 11224834
[TBL] [Abstract][Full Text] [Related]
7. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
Marchetti A; Lau H; Magar R; Wang L; Devercelli G
Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
[TBL] [Abstract][Full Text] [Related]
8. The impact of severe respiratory syncytial virus on the child, caregiver, and family during hospitalization and recovery.
Leidy NK; Margolis MK; Marcin JP; Flynn JA; Frankel LR; Johnson S; Langkamp D; Simoes EA
Pediatrics; 2005 Jun; 115(6):1536-46. PubMed ID: 15930214
[TBL] [Abstract][Full Text] [Related]
9. Burden of Respiratory Syncytial Virus Hospitalizations in Canada.
Mitchell I; Defoy I; Grubb E
Can Respir J; 2017; 2017():4521302. PubMed ID: 29311757
[TBL] [Abstract][Full Text] [Related]
10. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
11. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks.
Figueras-Aloy J; Carbonell-Estrany X; Quero-Jiménez J; Fernández-Colomer B; Guzmán-Cabañas J; Echaniz-Urcelay I; Doménech-Martínez E;
Pediatr Infect Dis J; 2008 Sep; 27(9):788-93. PubMed ID: 18664927
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of the respiratory syncytial virus risk-scoring tool in the term infant in Canada.
Paes B; Cole M; Latchman A; Pinelli J
Curr Med Res Opin; 2009 Sep; 25(9):2191-6. PubMed ID: 19604126
[TBL] [Abstract][Full Text] [Related]
13. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
Paes B; Steele S; Janes M; Pinelli J
Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
[TBL] [Abstract][Full Text] [Related]
14. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
[TBL] [Abstract][Full Text] [Related]
15. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention.
Stewart DL; Romero JR; Buysman EK; Fernandes AW; Mahadevia PJ
Curr Med Res Opin; 2009 Nov; 25(11):2795-804. PubMed ID: 19788406
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology of respiratory syncytial virus infection in infants born at less than thirty-five weeks of gestational age.
Park HW; Lee BS; Kim AR; Yoon HS; Kim BI; Song ES; Kim WT; Lim J; Kim S; Jin HS; Byun S; Chee DH; Kim KS
Pediatr Infect Dis J; 2012 Aug; 31(8):e99-104. PubMed ID: 22531234
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany.
Liese JG; Grill E; Fischer B; Roeckl-Wiedmann I; Carr D; Belohradsky BH;
Eur J Pediatr; 2003 Apr; 162(4):230-6. PubMed ID: 12647195
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
Hampp C; Kauf TL; Saidi AS; Winterstein AG
Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
[TBL] [Abstract][Full Text] [Related]
19. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
[TBL] [Abstract][Full Text] [Related]
20. Hospitalization for respiratory syncytial virus bronchiolitis and disease severity in twins.
Dotan M; Ashkenazi-Hoffnung L; Samra Z; Livni G; Yarden-Bilavsky H; Amir J; Bilavsky E
Isr Med Assoc J; 2013 Nov; 15(11):701-4. PubMed ID: 24511652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
